Stragen

Stragen is a Swiss pharmaceutical company headquartered in Geneva that specializes in the development and commercialization of complex generic drugs and niche specialty medicines. Founded in 1990, the company focuses on high-barrier products within therapeutic areas such as oncology, critical care, women's health, and neurology. Stragen's portfolio includes a significant number of hospital-grade injectables and specialized oral formulations designed to meet unmet medical needs. The company operates a hybrid business model, utilizing direct sales forces in key European markets while maintaining a global network of licensing and distribution partners. In 2021, Stragen was acquired by the healthcare private equity firm ArchiMed to accelerate its international growth and pipeline expansion. The group is recognized for its expertise in navigating complex regulatory environments and managing sophisticated supply chains for difficult-to-manufacture pharmaceuticals.